1. Jazz Pharmaceuticals to participate in the Needham Healthcare Conference. 2. Management will hold a fireside chat on April 9, 2025. 3. Webcast will be available on the company’s investor section. 4. Jazz has a portfolio aimed at serious diseases, including oncology. 5. The event could enhance visibility among investors and analysts.
Participation in high-profile conferences tends to attract investor interest and may lead to increased stock activity. Historically, similar events have positively influenced biopharma stocks based on information disclosure and management's insights on pipeline advancements.
The conference may provide insights into Jazz's strategy and pipeline, influencing future investment. However, without major announcements expected, the impact is moderate.
The event's direct effects are expected around the conference date, largely influencing immediate trading behavior rather than long-term valuation.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 9, 2025, at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST.
An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 637 2141
U.S. +1 215 867 4948
SOURCE Jazz Pharmaceuticals plc